Pharma Company Bags Order Worth Rs 150-180 Million From Tamil Nadu Medical Services Corporation

The company has a market cap of over Rs 300 crore and the stock is up by 1.6 per cent from its 52-week low of Rs 635 per share.

Fredun Pharmaceuticals Limited (BSE: 539730), a leading provider of pharmaceuticals and innovative healthcare solutions for Pharmaceutical & veterinary applications, is pleased to announce that it has been awarded a significant tender by the Tamil Nadu Medical Services Corporation (TNMSC) for the supply of generic medicines. The total value of the tender ranges between Rs 150 million and Rs 180 million.

The supply of these goods is set to commence within the first quarter of FY26 and will extend over a period of 14 months. This development underlines Fredun Pharma’s commitment to providing high-quality and affordable healthcare solutions to the community. The products will be part of the Fredun Gx brand, which is known for its dedication to excellence and reliability. This tender award from TNMSC not only reinforces our position in the market but also aligns with our mission to enhance access to essential medications for all.

Fredun Pharmaceuticals Limited, a healthcare and pharmaceuticals company, offer a range of products, including antihypertensives, antidiabetics, antiretroviral drugs (ARVs) and narcotics. It is also engaged in the manufacturing of dietary/herbal supplements, nutraceuticals, cosmeceuticals, and other healthcare products, along with animal healthcare products.

With such a diverse range of products, the Company’s objective is to be a holistic healthcare provider. The Company primarily exports its products to Africa, Southeast Asia, Commonwealth of Independent States (CIS) countries and Latin America. The company has a market cap of over Rs 300 crore and the stock is up by 1.6 per cent from its 52-week low of Rs 635 per share. Investors should keep an eye on this pharma stock.

Disclaimer: The article is for informational purposes only and not investment advice.